CEO HBA Support. Experienced patient advocate & specialist. Founding Vice Chair, Participant Panel, Genomics England. Member NHS Strategic Implementation Group, Generation Study, Former PR Managing Director & Journalist
A month to go before the Cell and Gene Therapy Summit in Brussels. Delighted to be invited back and looking forward to discussing and learning about the developments in the past year. This is an incredibly exciting time. Our understanding of what is possible is growing exponentially and we're seeing treatments and research programmes come through that were unheard of a decade ago, such as the Genomics England Rare Disease Launchpad*, a new programme that will develop a pathway for children with rare conditions to access individualised therapies. What will lie ahead in the next decade? Are patient and public opinions changing as fast as the scientific advances? With this pace, comes a natural anxiety. Worries about the possible consequence of therapies are countered by the argument to move faster and treat more people - young and old - with rare diseases sooner. Only with increased patient/public understanding and meaningful engagement can we look to address this challenge and embrace life-changing opportunities. Patients and the public need to be part of the journey ahead. #EconCellGeneTherapySummit Michele Salter Chris Fearne & Alastair Kent Hereditary Brain Aneurysm Support * https://lnkd.in/e8ezJXKN
The cost of CGTs is immense, ranging from hundreds of thousands of dollars to millions for each patient. How can novel financial approaches be developed to keep the costs of CGTs from being prohibitive for patients? This event will bring together healthcare stakeholders to discuss how pricing and delivery models can be modernised to keep up with the science and how equitable access can be ensured. Join us in Brussels, April 15th and 16th, to discuss this and more. Get 30% off your early bird delegate pass before 20th March with code CPDCGT. Register here: http://econimpact.co/k8 #EconCellGeneTherapySummit
